S&P 500
7,507.80
-0.22%
Dow Jones
51,595.40
-0.32%
Nasdaq 100
30,411.80
-0.23%
Russell 2000
2,975.48
-0.09%
FTSE 100
10,384.80
-0.34%
Nikkei 225
71,987.20
+0.02%

Investing

Bristol-Myers Squibb (BMY) To Buy Inhibitex (IHNX)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published

Bristol-Myers (NYSE: BMY) will buy Inhibitex (NASDAQ: IHNX) for $26 a share about 2.5x what the smaller company’s shares traded for on Friday. The entire consideration, all in case, for Inhibitex, is $2.5 billion.

BMY said it made the deal to get valuable biopharma products and research.

The big pharma said

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections, whose primary focus is on the development of nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV). Its lead HCV asset is INX-189, an oral nucleotide polymerase (NS5B) inhibitor in Phase II development that has exhibited potent antiviral activity, a high barrier to resistance and pan-genotypic coverage. Nucleotides/nucleosides are emerging as an important class of antivirals that may play a critical role as the backbone of future direct-acting antiviral-only combination approaches to HCV treatment.

Follow 24/7 Wall St. on Google
Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Atea Pharma Announces Potential Pricing for IPO
Chris Lange |

Atea Pharma Announces Potential Pricing for IPO

Clinical-stage biopharmaceutical company Atea Pharma intends to price 11 million shares for and intial public offering valued up to more…

Douglas A. McIntyre |

Biotech Implosion: Idenix Pharmaceuticals (IDIX)

Idenix Pharma (NASDAQ:IDIX) this morning announced that its Valopicitabine development program was placed on clinical hold in the United States…

Spring Bank Pharmaceuticals Scales Back IPO
Chris Lange |

Spring Bank Pharmaceuticals Scales Back IPO

Spring Bank Pharmaceuticals expects to price more than a million shares in the range of $12 to $14 per share…

Chris Lange |

Arrowhead Jumps in Anticipation of Analyst Day

Arrowhead Research shares soared in early trading indications Thursday in anticipation of its analyst day.

Jon C. Ogg |

Chimerix Wants Its Piece of the Ebola Pie

Chimerix has announced that its lead drug candidate has been provided for potential use in patients with Ebola virus disease.

ContraVir Pharma Takes Off on Positive Results
Chris Lange |

ContraVir Pharma Takes Off on Positive Results

ContraVir Pharmaceuticals led the bulls early on Tuesday following the release of positive hepatitis B results.

Stock Futures Surge as Gilead’s Remdesivir Could Be COVID-19 Top Treatment Candidate
Jon C. Ogg |

Stock Futures Surge as Gilead’s Remdesivir Could Be COVID-19 Top Treatment Candidate

While the COVID-19 pandemic wrecked the stock market and the economy, the recent rally in the stock market has been…

Jon C. Ogg |

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

ThinkstockIdenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on Friday with a rally of 40%.…

Keytruda, COVID-19 Hopes Prompt Merck Earnings Beat, Rosy Outlook
Chris Lange |

Keytruda, COVID-19 Hopes Prompt Merck Earnings Beat, Rosy Outlook

When Merck & Co. (NYSE: MRK | MRK Price Prediction) reported its second-quarter financial results before the markets opened on…

Top Gaining Stocks

CarMax
KMX • Vol: 7,330,419
Corning
GLW • Vol: 22,800,969
Intel
INTC • Vol: 233,719,006
Super Micro Computer
SMCI • Vol: 68,465,534
Enphase Energy
ENPH • Vol: 13,978,376

Top Losing Stocks

Accenture
ACN • Vol: 41,744,333
EPAM Systems
EPAM • Vol: 5,636,587
Cognizant
CTSH • Vol: 61,311,400
Coterra Energy
CTRA • Vol: 73,319,495
Kroger
KR • Vol: 26,704,230